John Mull buying at Cipher Pharmaceuticals (T:CPH)

John Mull, a 10% Holder, acquired 23,500 Common Shares on an indirect ownership basis for registered holder 1207407 Ontario Limited at a price of $5.550 between June 9th and 14th, 2017. This represents a $130,425 investment into the company's shares and an account share holdings change of 0.3%.

Cipher Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States. Cipher Pharmaceuticals Inc. (CPH) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $130,425.